ReferIndia News FDA Cracks Down on Copycat Drug Market Amid Hims Controversy

ReferIndia News

Sponsored

Easy Steps, Real Earnings

Start Earning
News Image

FDA Cracks Down on Copycat Drug Market Amid Hims Controversy

Published on: Feb. 6, 2026, 7:46 a.m. | Source: Devdiscourse

The FDA is set to take action against companies selling unapproved copycat drugs, as seen in the case of Hims and Hers Health marketing a cheaper version of Novo Nordisk's Wegovy weight-loss pill. The compounded drug lacks FDA approval, raising concerns about safety and efficacy.

Checkout more news
Ad Banner

One Partner for All Your Financial Goals

From financial planning and insurance to portfolio management and retirement solutions—get everything under one trusted roof.

Book Consultation
ReferIndia News contact